Search results
Showing 826 to 840 of 1877 results for do not dos
This quality standard covers routine postnatal care in the first 8 weeks after birth. It describes high-quality care in priority areas for improvement.
View quality statements for QS37Show all sections
Sections for QS37
- Quality statements
- Quality statement 1: Communication between healthcare professionals at transfer of care
- Quality statement 2: Information and advice about babies' feeding
- Quality statement 3: Symptoms and signs of illness in babies
- Quality statement 4: Face-to-face feeding support
- Quality statement 5: Safer practices for bed sharing
- Quality statement 6: GP postnatal check for women
- Quality statement 7: Advice on introducing solid food
High-throughput non-invasive prenatal testing for fetal RHD genotype (HTG420)
Evidence-based recommendations on high-throughput non-invasive prenatal testing (NIPT) for fetal RHD genotype.
This manual explains how NICE develops and updates social care guidance. It provides advice on the technical aspects of guidance development and the methods used
NICE has developed a medtech innovation briefing (MIB) on Optowire for measuring fractional flow reserve .
This quality standard covers diagnosing and managing multiple sclerosis (MS) in adults. It includes care, support and review for people with MS. It describes high-quality care in priority areas for improvement.
View quality statements for QS108Show all sections
This quality standard covers care and support for adults with cerebral palsy (aged 25 and over). It describes high-quality care in priority areas for improvement.
View quality statements for QS191Show all sections
Low-energy contact X-ray brachytherapy for rectal cancer (HTG763)
Evidence-based recommendations on low-energy contact X-ray brachytherapy for rectal cancer. This involves inserting an X-ray tube through the anus into the rectum. The tube is placed in contact with the tumour and releases a low dose of X-ray radiation (brachytherapy) directly to it.
Implanted vagus nerve stimulation for treatment-resistant depression (HTG551)
Evidence-based recommendations on vagus nerve stimulation for treatment-resistant depression in adults. This involves implanting an electrical stimulator under the skin of the chest and connecting it by wires to the vagus nerve.
View recommendations for HTG551Show all sections
Genicular artery embolisation for pain from knee osteoarthritis (HTG595)
Evidence-based recommendations on genicular artery embolisation for pain from knee osteoarthritis. This involves inserting a tube through an artery in the groin into the genicular artery, and injecting tiny particles through it to block new blood vessels.
View recommendations for HTG595Show all sections
Nerve transfer to partially restore upper limb function in tetraplegia (HTG466)
Evidence-based recommendations on nerve transfer to partially restore upper limb function in people with tetraplegia. This involves connecting an undamaged, functioning, but non-essential nerve near the injury to the damaged essential nerve.
View recommendations for HTG466Show all sections
Endobronchial nerve ablation for chronic obstructive pulmonary disease (HTG604)
Evidence-based recommendations endobronchial nerve ablation for chronic obstructive pulmonary disease. This involves destroying (ablating) the nerves on the outside of the airway (endobronchial nerves) to improve breathing.
View recommendations for HTG604Show all sections
Mini/micro screw implantation for orthodontic anchorage (HTG152)
Evidence-based recommendations on mini/micro screw implantation for orthodontic anchorage. This involves inserting small screws into the jaw bone to create anchors that support tooth realignment.
View recommendations for HTG152Show all sections
Sections for HTG152
Extracorporeal whole liver perfusion for acute liver failure (HTG573)
Evidence-based recommendations on extracorporeal whole liver perfusion for acute liver failure. This involves blood being diverted to a whole liver (perfusion) outside the body and returned to the patient.
View recommendations for HTG573Show all sections
Risankizumab for previously treated moderately to severely active Crohn's disease (TA888)
Evidence-based recommendations on risankizumab (Skyrizi) for previously treated moderately to severely active Crohn's disease in people 16 years and over.
Evidence-based recommendations on tocilizumab (RoActemra) for treating giant cell arteritis in adults.